Inhibitory effects of ursodeoxycholic acid on the induction of nitric oxide synthase in vascular smooth muscle cells.

[1]  U. Förstermann,et al.  Nitric oxide synthase: expression and expressional control of the three isoforms , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  Y. Shiratori,et al.  Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases. , 2001, Japanese heart journal.

[3]  M. Liu,et al.  Cyclic GMP–Dependent Protein Kinase Expression in Coronary Arterial Smooth Muscle in Response to Balloon Catheter Injury , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[4]  W. Shin,et al.  Bile acids increase intracellular Ca2+ concentration and nitric oxide production in vascular endothelial cells , 2000, British journal of pharmacology.

[5]  S. Bannai,et al.  Effect of hypoxia on nitric oxide production and its synthase gene expression in rat smooth muscle cells. , 2000, Biochemical and biophysical research communications.

[6]  M. Makuuchi,et al.  Ursodeoxycholic acid in serum and liver tissue in patients with end-stage cholestatic liver cirrhosis. , 1999, Transplantation proceedings.

[7]  Sun-Mee Lee,et al.  Effect of ursodeoxycholic acid on ischemia/reperfusion injury in isolated rat heart , 1999, Archives of pharmacal research.

[8]  M. Shichiri,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Differential Inhibitory Actions by Glucocorticoid and Aspirin on Cytokine-Induced Nitric Oxide Production in Vascular Smooth Muscle Cells* , 2022 .

[9]  J. Vanoverschelde,et al.  Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque. , 1999, Cardiovascular research.

[10]  K. Kojima,et al.  Bile acids inhibit tumour necrosis factor α‐induced interleukin‐8 production in human colon epithelial cells , 1998, Journal of gastroenterology and hepatology.

[11]  M. Shichiri,et al.  Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. , 1998, Circulation.

[12]  I. Makino,et al.  From a choleretic to an immunomodulator: Historical review of ursodeoxycholic acid as a medicament , 1998, Journal of gastroenterology and hepatology.

[13]  L. Theilmann,et al.  Adjuvant treatment with ursodeoxycholic acid may reduce the incidence of acute cardiac allograft rejection. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  G. Hansson,et al.  Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. , 1998, Circulation research.

[15]  R. Hruban,et al.  Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft arteriosclerosis. , 1997, The American journal of pathology.

[16]  I. Sayek,et al.  Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice , 1997, The British journal of surgery.

[17]  M. O’connor,et al.  Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo. , 1997, The American journal of physiology.

[18]  K. Setchell,et al.  Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. , 1997, Gastroenterology.

[19]  G. Hansson,et al.  Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. , 1996, The American journal of pathology.

[20]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[21]  M. Yacoub,et al.  Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[22]  Y. Hattori,et al.  Ursodeoxycholic acid inhibits the induction of nitric oxide synthase. , 1996, European journal of pharmacology.

[23]  Y. Makino,et al.  Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. , 1996, Journal of immunology.

[24]  J. Isner,et al.  Apoptosis in human atherosclerosis and restenosis. , 1995, Circulation.

[25]  T. Gettys,et al.  Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: a role for PKC. , 1995, The American journal of physiology.

[26]  T. Ogihara,et al.  Nitric oxide mediates cytotoxicity and basic fibroblast growth factor release in cultured vascular smooth muscle cells. A possible mechanism of neovascularization in atherosclerotic plaques. , 1995, The Journal of clinical investigation.

[27]  A. Bhattacharyya,et al.  Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. , 1994, Cancer research.

[28]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[29]  F. Zwas,et al.  Ursodeoxycholic acid in the treatment of chronic liver disease. , 1994, The American journal of gastroenterology.

[30]  G. Hansson,et al.  Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury , 1994, The Journal of experimental medicine.

[31]  Luketic Va,et al.  The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease. , 1994 .

[32]  W. A. Bradley,et al.  Superoxide and peroxynitrite in atherosclerosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Tanaka,et al.  Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor. , 1992, Biochemical and biophysical research communications.

[34]  C. Nathan,et al.  Nitric oxide as a secretory product of mammalian cells , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  L. Mjörnstedt,et al.  Ursodeoxycholic acid reduces acute rejection in heart allografted rats. , 1992, Transplantation proceedings.

[36]  S. Moncada,et al.  Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? , 1991, The Lancet.

[37]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[38]  J. Bircher,et al.  Ursodeoxycholic acid–induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis , 1990, Hepatology.

[39]  C. Thiemermann,et al.  Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. , 1990, European journal of pharmacology.